Physician profile
Katherine Marie Newnam
NPI 1790921021
$1,604.81
in general payments reported to CMS, 2019-2025
13 companies · $393 in 2025
The $393 reported for 2025 was more than what 97% of Neonatal (Nurse Practitioner) providers received nationally (typical 2025 total: $40.24).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.51 · 2022: $284 · 2023: $364 · 2024: $507 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233 · Gift: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.48 |
| Gift | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $243.70 | 2023-2024 | Arexvy |
| Janssen Pharmaceuticals, INC | $228.78 | 2022 | |
| Janssen Biotech, INC. | $146.19 | 2025 | Tremfya |
| Abbvie INC. | $145.23 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $124.98 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $121.82 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals Lp | $121.82 | 2024 | Fasenra |
| Pharmacosmos Therapeutics INC. | $121.81 | 2023 | Monoferric |
| Genentech USA, INC. | $98.08 | 2024 | Xolair |
| Silk Road Medical, INC. | $95.71 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Daiichi Sankyo INC. | $69.18 | 2024 | |
| Novo Nordisk INC | $57.51 | 2021 | |
| Fisher & Paykel Healthcare Limited | $30.00 | 2023 | Fisher & Paykel Healthcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Newnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.